Cycling and medical supervision provide risk mitigation for those choosing longer-term use
Disclosures: Miroslava Subic Levrero: Gilead: Speaking and Teaching, AbbVieTravel grants: Travel Grants, Helene Fontaine: Nothing to Disclose, Victor de Ledinghen: Nothing to Disclose, Sophie Metivier: Nothing to Disclose, Philippe Mathurin: Nothing to Disclose, Laurent Alric: MSD, Abbvie, Sanofi: Speaking and Teaching, Caroline Lascoux Combe: Nothing to Disclose, Armand Abergel: Nothing to Disclose, Anne Gervais: Nothing to Disclose, Louis D'Alteroche: Nothing to Disclose, fatoumata Coulibaly: Nothing to Disclose, Estelle Le Pabic: Nothing to Disclose, Christelle Tual: Nothing to Disclose, Claire Fougerou-Leurent: Nothing to Disclose, Segolene Brichler: Nothing to Disclose, Fabien Zoulim: Nothing to Disclose 434 HBV TARGET SITE FOR THE RNA INTERFERENCE THERAPEUTIC IMDUSIRAN IS HIGHLY CONSERVED IN CHRONIC HEPATITIS B SUBJECTS Christine Espiritu 1 Andrzej Ardzinski 1 Holly Micolochick Steuer 1 Varun Sharma 1 Kevin Gray 1 Deana Antoniello 1 Timothy Eley 1 Karen Sims 1 Andrea Cuconati 1 Angela Lam 1 Michael Sofia 1 Emily Thi 1 , 1 Arbutus Biopharma, Warminster, PA, United States Background: Imdusiran (AB-729, IDR) is an N - Acetylgalactosamine-conjugated small interfering RNA (siRNA) currently being investigated in multiple combination studies, including pegylated interferon-alfa 2a (AB-729-201, IM-PROVE I) and the immunotherapeutic VTP-300 (AB-729-202, IM-PROVE II) for the treatment of chronic hepatitis B (CHB)
Easy Daily Use: Take 12 softgels daily with a meal
NADPH was then quantified via colorimetric assay (WST-8
Remember to patch test any new product and consult with a skincare professional if you have specific concerns
